biotech.today

Details

  • ●Modalities: antibodies, enzymes, cytokines, peptides, protein therapeutics
  • ●Therapeutic areas: immunology, oncology, infectious disease
  • ●Key targets: undisclosed protein targets
  • ●Indications: undisclosed
  • ●Funding: $573M+

Partners & investors

  • Flagship Pioneering· Investor
  • Samsung Life Science Fund· Investor
  • T. Rowe Price· Investor
  • ARCH Venture Partners· Investor

Key considerations

  • ●AI tools in use: Chroma (generative protein model), Proprietary generative biology platform, Large-scale protein language models
  • ●Chroma: generative model for protein structures (2023)
  • ●$273M Series C (Sept 2023)
  • ●Samsung Life Science Fund investment (Dec 2024)

Pipeline

  • Phase 11
Get live updates on Generate:Biomedicines’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Mike Nally

CEO

biotech leadershipcommercial strategy

Gevorg Grigoryan

Co-Founder & Chief Technology Officer

protein designcomputational biologymachine learning
Visit website →LinkedIn →